ABG-WTT Discloses $10.4M Portfolio, Concentrated in Biotech

TL;DR

**ABG-WTT's $10.4M portfolio is 100% in two biotech stocks, ACELRX and BIOCRYST, signaling high conviction but also high risk.**

AI Summary

ABG-WTT Global Life Science Capital Partners GP Ltd, a relatively small investment manager, filed its 13F-HR on May 15, 2024, disclosing a total portfolio value of $10,400,000 as of March 31, 2024. The filing reveals a highly concentrated portfolio with significant positions in just two companies: $5,200,000 in shares of ACELRX PHARMACEUTICALS INC and $5,200,000 in shares of BIOCRYST PHARMACEUTICALS INC. This matters to investors because such high concentration in a small portfolio indicates a high-conviction strategy, but also exposes them to significant risk if either of these specific biotech investments underperforms.

Why It Matters

This filing provides transparency into ABG-WTT's investment strategy, showing a strong focus on specific biotechnology companies, which can influence market sentiment for those stocks.

Risk Assessment

Risk Level: high — The portfolio's extreme concentration in only two biotechnology companies creates high risk due to lack of diversification and sector-specific volatility.

Analyst Insight

Investors should note ABG-WTT's high-conviction, concentrated biotech strategy. While this could lead to significant gains if their picks perform well, it also carries substantial risk due to lack of diversification. Those considering ACELRX or BIOCRYST should view this as a vote of confidence from a specialized fund, but conduct their own due diligence on the underlying companies.

Key Numbers

• $10.4M — Total Portfolio Value (The entire market value of ABG-WTT's disclosed holdings as of March 31, 2024.)
• $5.2M — ACELRX PHARMACEUTICALS INC Position (The market value of ABG-WTT's investment in ACELRX PHARMACEUTICALS INC, representing 50% of the total portfolio.)
• $5.2M — BIOCRYST PHARMACEUTICALS INC Position (The market value of ABG-WTT's investment in BIOCRYST PHARMACEUTICALS INC, representing 50% of the total portfolio.)
• 2 — Number of Holdings (The total number of distinct securities held in the portfolio, indicating extreme concentration.)

Key Players & Entities

• ABG-WTT Global Life Science Capital Partners GP Ltd (company) — the investment manager filing the 13F-HR
• ACELRX PHARMACEUTICALS INC (company) — a company in which ABG-WTT holds a significant position
• BIOCRYST PHARMACEUTICALS INC (company) — a company in which ABG-WTT holds a significant position
• $10,400,000 (dollar_amount) — total market value of the portfolio as of March 31, 2024
• May 15, 2024 (date) — the filing date of the 13F-HR
• March 31, 2024 (date) — the reporting period end date for the portfolio holdings

Forward-Looking Statements

• ABG-WTT will likely maintain a highly concentrated portfolio in the biotech sector. (ABG-WTT Global Life Science Capital Partners GP Ltd) — high confidence, target: Next 13F-HR filing (August 2024)
• The performance of ACELRX PHARMACEUTICALS INC and BIOCRYST PHARMACEUTICALS INC will heavily dictate ABG-WTT's overall portfolio returns. (ACELRX PHARMACEUTICALS INC, BIOCRYST PHARMACEUTICALS INC) — high confidence, target: Ongoing

FAQ

Filing Documents

• primary_doc.html (13F-HR)
• primary_doc.xml (13F-HR) — 2KB
• 46413.html (INFORMATION TABLE)
• 46413.xml (INFORMATION TABLE) — 1KB
• 0001193125-25-283037.txt ( ) — 4KB

From the Filing

SEC FORM 13F-HR The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F COVER PAGE OMB APPROVAL OMB Number: 3235-0006 Estimated average burden hours per response: 23.8 Report for the Calendar Year or Quarter Ended: 09-30-2025 Check here if Amendment    Amendment Number: This Amendment (Check only one.):    is a restatement.    adds new holdings entries. Institutional Investment Manager Filing this Report: Name: ABG-WTT Global Life Science Capital Partners GP Ltd Address: SUITE 3902, 39/F, EAST TOWER CHEUNG KONG CNTR II, 10 HARCOURT ROAD CENTRAL, HONG KONG , K3   000000 Form 13F File Number: 028-20836 CRD Number (if applicable): The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Fan Yu Title: Director Phone: 852 31219699 Signature, Place, and Date of Signing: /s/ Fan Yu Todos Santos ,  O5 11-14-2025 [Signature] [City, State] [Date] Report Type (Check only one.): X 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)    13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)    13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) Form 13F Summary Page Report Summary: Number of Other Included Managers: 0 Form 13F Information Table Entry Total: 2 Form 13F Information Table Value Total: 18,675,589 (round to nearest dollar) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. [If there are no entries in this list, state “NONE” and omit the column headings and list entries.] NONE

View Full Filing

View this 13F-HR filing on SEC EDGAR